

Please, reply to: ced@ihi.or.tz

Location: DAR ES SALAAM

Ref.# IHI/CED/DSM/2025/1386

August 28, 2025

Dr. Henning Gädeke,
c/o Dr. Michael Makanga
Global Health EDCTP3 Joint Undertaking Governing
Board,
56 – 60 Avenue de la Toison d'Or,
1060 Brussels
Belgium.

Dear Sir/Madam,

RE: Letter of endorsement

On behalf of The Registered Trustees of Ifakara Health Institute (IHI), P. O. Box 78373, Kiko Avenue, 14112 Dar es Salaam, VAT number 108-256-451 and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

IHI is an independent, non-profit organisation, registered in Tanzania. It is one of Africa's most eminent health research organisations with a history of almost 70 years. The public health impact of our research is at the core of our mission and operations. IHI has a strong track record of influencing policy and practice through the translation of knowledge and research.

IHI brings expertise, experience, and necessary clinical facilities and laboratories for conducting Phase 1-IV trials. IHI has been instrumental in the evaluation of most of the major malaria vaccines, including "RTS, S/ASO1" and "R21/Matrix-MTM," which have both been recommended by WHO for rollout. IHI is currently evaluating vaccines against neglected diseases such as Rabies, human vaccines against zoonotic diseases such as Rift Valley fever, and emerging/re-emerging diseases such as Ebola, and establishing novel human challenge studies for malaria to support early evaluation of malaria interventions.

IHI has a dynamic group of experts leveraging advanced analytics, machine learning, and mathematical modelling to tackle complex public health challenges in Tanzania and beyond. Their work spans infectious diseases, such as malaria and tuberculosis, as well as non-communicable diseases, utilizing big data to uncover patterns and inform impactful interventions.

The Malaria Atlas Project – East Africa (MAP-EA) team at IHI specializes in high-resolution malaria risk mapping and geospatial analytics to support evidence-based decision-making across the region. The team also builds regional capacity through training, mentorship, and collaborative research, strengthening the foundation for sustainable malaria control and elimination. Their work bridges science and policy, ensuring data translates into impact.

Ifakara Branch

Off Mlabani Passage
P.O. Box 53 Ifakara
Phone: +255232625164

Dar es Salaam Office

Plot 463, Ifakara Street, Mikocheni
P.O. Box 78,373 Dar es Salaam
Phone: +255222774756

Bagamoyo Branch

Kingani Area
P.O. Box 74 Bagamoyo
Phone: +255232440065


IH also leads a national effort to monitor and combat antimalarial drug resistance and diagnostic challenges through cutting-edge genomic technologies, including qPCR, whole genome sequencing, and Oxford Nanopore. We also conduct serological and vector genomic surveillance, develop resistance models, and emphasize sustainable capacity building.

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes, and particularly the call conditions therein.
2. We will keep all information received in the context of our involvement as a contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular, but is not limited to, the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities, save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done based on the "need-to-know" principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Given our in-house expertise, IHI will contribute to Work Packages 3 and 5. We estimate the total value of our contribution at EUR 850,000, comprising both in-kind and financial support for activities over the five-year duration of the grant.

Yours sincerely,

DocuSigned by:

728BE860CB8A417...
Honorati Masanja, PhD
Chief Executive Director